Transarterial chemoembolization for liver metastases of a pancreatic neuroendocrine neoplasm: a single-center experience.
Liver metastasis
Pancreatic neuroendocrine tumor
Transarterial chemoembolization
Journal
Surgery today
ISSN: 1436-2813
Titre abrégé: Surg Today
Pays: Japan
ID NLM: 9204360
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
13
01
2023
accepted:
16
05
2023
medline:
28
11
2023
pubmed:
25
6
2023
entrez:
24
6
2023
Statut:
ppublish
Résumé
Transarterial chemoembolization (TACE) is performed for pancreatic neuroendocrine tumor (PanNEN) liver metastases; however, the safety and efficacy of TACE procedures, especially for patients who have undergone previous pancreatic surgery, have not been established. We reviewed 48 TACE procedures (1-6 procedures/patient) performed on 11 patients with PanNEN liver metastases, including 16 TACE procedures (4-6 procedures/patient) for 3 patients with a history of biliary-enteric anastomosis. The overall tumor objective response rate was 94%. The incidence of Clavien‒Dindo grade ≥ 2 complications was 1/16 (6%) and 1/32 (3%), and the median time to untreatable progression was 31 (14-41) and 27 (2-60) months among patients with and without a history of biliary-enteric anastomosis, respectively. Although validation is needed in future studies, our experiences have shown that TACE treatment is a viable treatment option for PanNEN liver metastases, even after biliary-enteric anastomosis with experienced teams and careful patient follow-up.
Identifiants
pubmed: 37355500
doi: 10.1007/s00595-023-02714-9
pii: 10.1007/s00595-023-02714-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1396-1400Informations de copyright
© 2023. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd.
Références
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.
doi: 10.1001/jamaoncol.2017.0589
pubmed: 28448665
pmcid: 5824320
Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009;16(3):885–94.
doi: 10.1677/ERC-09-0042
pubmed: 19458024
Zhou H, Zhang Y, Wei X, Yang K, Tan W, Qiu Z, et al. Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study. Cancer Med. 2017;6(11):2745–56.
doi: 10.1002/cam4.1220
pubmed: 28980417
pmcid: 5673917
Marchegiani G, Landoni L, Andrianello S, Masini G, Cingarlini S, D’Onofrio M, et al. Patterns of recurrence after resection for pancreatic neuroendocrine tumors: Who, when, and where? Neuroendocrinology. 2019;108(3):161–71.
doi: 10.1159/000495774
pubmed: 30481765
Cazzato RL, Hubelé F, De Marini P, Ouvrard E, Salvadori J, Addeo P, et al. Liver-directed therapy for neuroendocrine metastases: from interventional radiology to nuclear medicine procedures. Cancers (Basel). 2021;13(24):6368.
doi: 10.3390/cancers13246368
pubmed: 34944988
Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–76.
doi: 10.1159/000335597
pubmed: 22262022
Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, et al. The north American neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49(1):1–33.
doi: 10.1097/MPA.0000000000001454
pubmed: 31856076
pmcid: 7029300
Scigliano S, Lebtahi R, Maire F, Stievenart JL, Kianmanesh R, Sauvanet A, et al. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. Endocr Relat Cancer. 2009;16(3):977–90.
doi: 10.1677/ERC-08-0247
pubmed: 19470616
Kanabar R, Barriuso J, McNamara MG, Mansoor W, Hubner RA, Valle JW, et al. Liver embolisation for patients with neuroendocrine neoplasms: systematic review. Neuroendocrinology. 2021;111(4):354–69.
doi: 10.1159/000507194
pubmed: 32172229
De Jong MC, Farnell MB, Sclabas G, Cunningham SC, Cameron JL, Geschwind JF, et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg. 2010;252(1):142–8.
doi: 10.1097/SLA.0b013e3181dbb7a7
pubmed: 20531007
Kim W, Clark TW, Baum RA, Soulen MC. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol. 2001;12(8):965–8.
doi: 10.1016/S1051-0443(07)61577-2
pubmed: 11487677
de Baère T, Roche A, Amenabar JM, Lagrange C, Ducreux M, Rougier P, et al. Liver abscess formation after local treatment of liver tumors. Hepatology. 1996;23(6):1436–40.
doi: 10.1002/hep.510230620
pubmed: 8675161
Joskin J, de Baere T, Auperin A, Tselikas L, Guiu B, Farouil G, et al. Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor. Cardiovasc Intervent Radiol. 2015;38(2):372–80.
doi: 10.1007/s00270-014-0914-1
pubmed: 24873919
Maire F, Lombard-Bohas C, O’Toole D, Vullierme MP, Rebours V, Couvelard A, et al. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study. Neuroendocrinology. 2012;96(4):294–300.
doi: 10.1159/000336941
pubmed: 22507901
Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014;47(1):177–82.
doi: 10.1007/s12020-013-0130-9
pubmed: 24385266
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–23.
doi: 10.1056/NEJMoa1009290
pubmed: 21306238
pmcid: 4208619
Angelousi A, Kamp K, Kaltsatou M, O’Toole D, Kaltsas G, de Herder W. Sequential everolimus and sunitinib treatment in pancreatic metastatic well-differentiated neuroendocrine tumours resistant to prior treatments. Neuroendocrinology. 2017;105(4):394–402.
doi: 10.1159/000456035
pubmed: 28122378
Ito T, Tori M, Hashigaki S, Kimura N, Sato K, Ohki E, et al. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a phase II study. Jpn J Clin Oncol. 2019;49(4):354–60.
doi: 10.1093/jjco/hyz009
pubmed: 30834940
pmcid: 6452620
Birgin E, Téoule P, Galata C, Rahbari NN, Reissfelder C. Cholangitis following biliary-enteric anastomosis: a systematic review and meta-analysis. Pancreatology. 2020;20(4):736–45.
doi: 10.1016/j.pan.2020.04.017
pubmed: 32386969
Bhagat N, Reyes DK, Lin M, Kamel I, Pawlik TM, Frangakis C, et al. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol. 2013;36(2):449–59.
doi: 10.1007/s00270-012-0424-y
pubmed: 22722717
Guiu B, Deschamps F, Aho S, Munck F, Dromain C, Boige V, et al. Liverbiliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma lipiodol vs drug-eluting beads. J Hepatol. 2012;56(3):609–17.
doi: 10.1016/j.jhep.2011.09.012
pubmed: 22027582